CGON
CGON
NASDAQ · Biotechnology

Cg Oncology Inc

$65.81
+1.97 (+3.09%)
As of Mar 25, 9:56 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.64M
Net Income
-127,308,493
Gross Margin
Profit Margin
-7,729.5%
Rev Growth
-52.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 55.1% 55.1%
Operating Margin -10,067.2% -9,060.5% -15.6% -13.7%
Profit Margin -7,729.5% -7,343.0% -17.7% -17.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.64M 3.43M 1.61B 1.48B
Gross Profit 888.76M 815.58M
Operating Income -165,585,020 -311,055,140 -251,110,084 -202,451,059
Net Income -127,308,493 -239,151,834 -285,460,132 -250,904,762
Gross Margin 55.1% 55.1%
Operating Margin -10,067.2% -9,060.5% -15.6% -13.7%
Profit Margin -7,729.5% -7,343.0% -17.7% -17.0%
Rev Growth -52.1% -52.1% +15.2% +12.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.65B 1.56B
Total Equity 2.51B 2.29B
D/E Ratio 0.66 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -165,762,219 -328,687,347 -344,556,820 -320,224,465
Free Cash Flow -296,727,069 -277,168,820